GlaxoSmithKline

HGS’s Benlysta grosses $59 million

Wednesday, January 11, 2012 11:05 AM

Benlysta (belimumab), the first approved drug for systemic lupus in 56 years, has already grossed $59.2 million, averaging $2.3 million in sales per week since it received FDA approval less than a year ago, according to Human Genome Sciences (HGS).

More... »


AVI BioPharma names senior VP

Tuesday, December 13, 2011 12:18 PM

AVI BioPharma has named Jayant Aphale, Ph.D., senior vice president of technical operations. Aphale will have responsibility for all of AVI's internal and outsourced manufacturing activities, with an emphasis on technology transfer, scale-up, CMC compliance, CMC regulatory issues, and CMC project management from initial development through commercial production.

More... »


Report: Boston, N.J., Bay area lead nation’s top 16 life sciences clusters, all are growing

Monday, December 5, 2011 09:18 AM

Move over Boston, New Jersey and the San Francisco Bay area. Los Angeles and the Washington, D.C., region are quickly gathering steam as established life sciences hubs. And Minneapolis, Chicago, Denver, Houston, Florida, Atlanta and Indianapolis are among the emerging hubs not far behind. 

More... »

UCB inks strategic partnerships with Parexel, PRA

Monday, November 28, 2011 08:00 AM

The sponsor-CRO strategic partnerships just keep coming. 

More... »

GSK launches $50 million Canada Life Sciences Innovation Fund

Tuesday, November 15, 2011 12:05 PM

GlaxoSmithKline has launched the GSK Canada Life Sciences Innovation Fund, a new national $50 million fund that will significantly advance the commercialization of scientific innovation in Canada by investing in early stage breakthrough research. The fund will identify strategic investment opportunities within Canada’s life sciences industry including academic and health institutions, translational research centres and start-up companies.

More... »

Signum, GlaxoSmithKline ink research agreement

Thursday, November 10, 2011 10:09 AM
Signum Biosciences has entered into an agreement with GlaxoSmithKline to collaborate on Signum's phosphatase screening technology and Phosphoprotein Phosphatase 2A (PP2A). The agreement provides Signum with research support and milestone payments. GSK receives the exclusive right of Signum's proprietary phosphatase screening technology for GSK's research and development activities in neurosciences.

More... »

Alnylamm, GSK collaborate in vaccine production

Thursday, November 3, 2011 01:13 PM

Alnylam Pharmaceuticals has formed a collaboration with GlaxoSmithKline focused on Alnylam's VaxiRNATM technology for certain GSK vaccine products, including influenza. VaxiRNA is a new RNAi technology for the enhanced production of viruses used in the manufacture of vaccine products. GSK is the first company to form a collaboration accessing this new platform.

More... »

GSK, University of Edinburgh partner in drug discovery

Wednesday, October 26, 2011 12:53 PM

GlaxoSmithKline (GSK) and the University of Edinburgh have agreed on a collaborative partnership to discover and develop medicines with the potential to treat severe acute pancreatitis.

More... »

Life Technologies, GSK ink cancer research agreement

Wednesday, October 26, 2011 10:55 AM

Life Technologies has signed an agreement with GlaxoSmithKline to develop a diagnostic to be used as a companion test with a GSK candidate cancer immunotherapy. Life will develop a qPCR-based molecular diagnostic assay for GSK's MAGE-A3 cancer immunotherapy candidate designed to identify patients likely to benefit from the immunotherapy.

More... »

Eagle Awards honor GSK, Medpace, Quorum IRB

Friday, October 21, 2011 11:14 AM

Sponsor GlaxoSmithKline, CRO Medpace and IRB Quorum Review all took home the coveted Eagle Award last Saturday, honored by investigative sites at the sixth annual Site Solutions Summit.

More... »


CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013

Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings

Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving

Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs